Abstract
Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Protein & Peptide Letters
Title:Engineering Novel Anticoagulant Proteins by Motif Grafting
Volume: 21 Issue: 2
Author(s): Yuanjun Zhu, Aihua Liu, Xiaoyan Liu and Yinye Wang
Affiliation:
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Abstract: Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Export Options
About this article
Cite this article as:
Zhu Yuanjun, Liu Aihua, Liu Xiaoyan and Wang Yinye, Engineering Novel Anticoagulant Proteins by Motif Grafting, Protein & Peptide Letters 2014; 21 (2) . https://dx.doi.org/10.2174/092986652102131226112049
DOI https://dx.doi.org/10.2174/092986652102131226112049 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Activities of Pyrazoline Derivatives -A Recent Development
Recent Patents on Anti-Infective Drug Discovery Meet Our Editorial Board Member
Current Nanomaterials Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective
Current Pharmaceutical Design Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation
Current Topics in Medicinal Chemistry Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Structure-Activity Relationships of Histamine H1-Receptor Agonists
Mini-Reviews in Medicinal Chemistry Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Development of Radioligands for Imaging of Brain Norepinephrine Transporters In Vivo with Positron Emission Tomography
Current Topics in Medicinal Chemistry Discovery of Hybrid Purine-quinoline Molecules and Their Cytotoxic Evaluation
Letters in Drug Design & Discovery Vitamin D and its Possible Relationship to Neuroprotection in COVID-19: Evidence in the Literature
Current Topics in Medicinal Chemistry Drug Therapy in Schizophrenia
Current Pharmaceutical Design Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry Update on Antifolate Drugs Targets
Current Drug Targets Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction
Medicinal Chemistry Efficient Synthesis of Fused Pyrimidine Derivatives with Biological Activity via Aza-Wittig Reaction
Current Organic Synthesis An Updated Review on <i>Betacoronavirus</i> Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery
Current Topics in Medicinal Chemistry Foreword:
Mini-Reviews in Organic Chemistry Enzyme Inhibitors
Current Bioactive Compounds Novel, Acidic CCR2 Receptor Antagonists: From Hit to Lead
Letters in Drug Design & Discovery